 ROCKVILLE, Md. and BEIJING, June 10, 2021 PRNewswire -- CASI Pharmaceuticals, Inc. Nasdaq: CASI, a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma. 